Posted on February 6, 2018
CAMH is part of a national study to improve treatment for people with problems with prescription opioid medications, and you may be eligible to take part in our study.
Recently, problematic use of prescription opioids – also called prescription opioid use disorder – has increased drastically in Canada. Related harms, including hospitalizations and deaths from overdose, have also increased substantially. It’s estimated that prescription opioid use disorder accounts for the third-highest burden of disease related to substance use, after alcohol and tobacco.
There are two medications approved in Canada to treat opioid use disorder: methadone and a combination of buprenorphine and naloxone. Although methadone has long been the standard of care for treatment, there is growing consensus that buprenorphine and naloxone may offer advantages. Our study will compare and evaluate the two medications to improve care for people with prescription opioid use disorder.
We are looking for participants who:
• are 18 to 64 years of age,
• have been diagnosed with prescription opioid use disorder, and
• are seeking treatment (but have not yet begun treatment).
People who take part in the study will receive treatment for 24 weeks. During this time, you will come to our downtown Toronto clinic for 15 study visits to monitor how you respond to the medication. The first two visits will take 3 to 4 hours, and the follow-up visits will take about an hour to 1.5 hours. Participants will receive compensation for their time.
To learn more or ask about joining our study, call us at 416-535-8501 ext. 39225.
You can also find our study details in our CAMH study listing.
CAMH REB number: 127/2016